FIELD: biotechnology.
SUBSTANCE: invention refers to producing a molecule specifically bound to HBsAg, CD3 and CD28, and can be used in medicine.
EFFECT: obtained binding molecule consists of two polypeptides with SEQ ID NO: 43 and SEQ ID NO: 44, interconnected by leucine zipper, and can be used for effective treatment or prevention of HVB infection or condition caused by said HVB infection.
4 cl, 9 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| MULTIVALENT Fv-ANTIBODIES | 2016 |
|
RU2785766C2 |
| POLYPEPTIDE FOR TREATING PATHOLOGICAL BLOOD CLOTS | 2019 |
|
RU2778566C1 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| DELIVERY OF THERAPEUTIC POLYPEPTIDES VIA PSEUDOTYPED ONCOLYTIC VIRUSES | 2017 |
|
RU2758007C2 |
| IMPROVED REP PROTEIN FOR USE IN DIAGNOSTIC ANALYZES | 2018 |
|
RU2736275C1 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| INDUCIABLE BINDING PROTEINS AND THEIR USE | 2017 |
|
RU2800034C2 |
| 5T4 AND 4-1BB ANTIGEN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | 2018 |
|
RU2804458C2 |
| BISPECIFIC BINDING PROTEINS AND APPLICATION WAYS THEREOF | 2017 |
|
RU2766199C2 |
